Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | AMEX | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 16, 23 | -0.08 Increased by +38.46% | -0.11 Increased by +247.93% |
| May 15, 23 | -0.08 Increased by +20.00% | -0.11 Increased by +247.93% |
| May 12, 23 | -0.08 Increased by 0.00% | -0.11 Increased by +247.93% |
| Mar 16, 23 | -0.09 Decreased by -12.50% | -0.12 Increased by +208.33% |
| Nov 15, 22 | -0.13 Decreased by -8.33% | -0.08 Decreased by -781.25% |
| Aug 15, 22 | -0.10 Decreased by -25.00% | -0.07 Decreased by -612.24% |
| May 16, 22 | -0.08 Increased by +33.33% | -0.07 Decreased by -204.08% |
| May 13, 22 | -0.08 Increased by +33.33% | -0.07 Decreased by -204.08% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 49.00 K Increased by +48.48% | -2.85 M Increased by +36.56% | Decreased by -5.81 K% Increased by +57.28% |
| Dec 31, 22 | 56.00 K Increased by +12.00% | -4.30 M Increased by +25.23% | Decreased by -7.67 K% Increased by +33.25% |
| Sep 30, 22 | 21.00 K Decreased by -36.36% | -6.25 M Decreased by -63.33% | Decreased by -29.76 K% Decreased by -156.66% |
| Jun 30, 22 | 30.00 K Increased by +30.43% | -5.01 M Increased by +14.79% | Decreased by -16.69 K% Increased by +34.67% |
| Mar 31, 22 | 33.00 K Increased by +17.86% | -4.49 M Decreased by -25.40% | Decreased by -13.60 K% Decreased by -6.40% |
| Dec 31, 21 | 50.00 K Increased by +19.05% | -5.75 M Decreased by -46.06% | Decreased by -11.49 K% Decreased by -22.69% |
| Sep 30, 21 | 33.00 K Decreased by -8.33% | -3.83 M Decreased by -15.73% | Decreased by -11.59 K% Decreased by -26.25% |
| Jun 30, 21 | 23.00 K Decreased by -42.50% | -5.88 M Decreased by -74.36% | Decreased by -25.55 K% Decreased by -203.24% |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.